June 2026
Depression
What June 2026's 25 new studies found, synthesized from the papers below. All Depression research →
The synthesis
Synthesized from 25 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Depression, major depressive disorder, MDD, depressive disorder, treatment-resistant depression, then ranked by relevance.
Research published in June 2026 indicates that both mindfulness-based interventions and rapid-acting antidepressants (ketamine, esketamine, psilocybin) show promise for depression, with mindfulness consistently reducing symptoms and psychedelics/ketamine providing rapid relief, especially in treatment-resistant cases. However, evidence is mixed regarding long-term durability, and many studies are limited by small samples, lack of blinding, or short follow-up periods.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Mindfulness training accelerates anxiety and depression relief via enhanced psychological resilience 2026 | RCT | 133 | Supports | Mindfulness training significantly reduced anxiety and depression symptoms compared to control, with psychological resilience partially mediating these improvements. |
| Ketamine renaissance: Expanding horizons from anesthesia to depression and pain 2026 | review | Supports | Ketamine offers rapid antidepressant effects in treatment-resistant depression and efficacy in pain, but long-term safety and protocol standardization remain unresolved. | |
| Chronic psilocin microdosing produces limited behavioral effects and does not enhance neurogenesis in rats. 2026 | preclinical experimental study | No effect | Chronic psilocin microdosing did not affect depressive-like behavior, sociability, or neurogenesis, though a small anxiogenic effect was observed. | |
| Psychotherapy and Ketamine: How Does This Combination Affect the Duration of the Antidepressant Effect? 2026 | review | Mixed | Psychotherapy combined with ketamine may moderately prolong antidepressant effects, but data are heterogeneous and one study showed no advantage over ketamine monotherapy. | |
| Prevalence of Stress, Anxiety, and Depression and the Effectiveness of a Mindfulness-Based Life Coaching Intervention among 4th-Year Medical Students: A Pilot Quasi- Experimental Study 2026 | cross-sectional screening followed by single-arm pre-post intervention | 100 | Supports | A 21-day mindfulness-based life coaching program was associated with significant reductions in stress, anxiety, and depression among medical students with mild-to-moderate distress. |
| Psychedelics in treatment-resistant depression: a comprehensive review of mechanisms, clinical evidence, and recommendations. 2026 | review | Supports | Psychedelics, particularly psilocybin, ketamine, esketamine, and ayahuasca, show promise for treatment-resistant depression through mechanisms including neuroplasticity and corticolimbic enhancement. | |
| Esketamine multi-omic biomarker evaluation in major depressive disorder (EMBER-MDD): concept, objectives and methodologies of a non-clinical investigator-initiated study. 2026 | non-interventional, investigator-initiated, in-vitro study | 420 | Unclear | This study aims to discover biomarkers associated with treatment resistance risk and molecular correlates of clinical response to esketamine nasal spray versus treatment as usual. |
| Comprehensive Systematic Review of Esketamine Nasal Spray as a Standalone Rapid-Acting Treatment for Treatment-Resistant Depression: Integrating Clinical Trial Data and Emerging Real-World Evidence on Efficacy, Safety, And Relapse Prevention 2026 | review | Supports | Esketamine reduces depressive symptoms more effectively than placebo or quetiapine, with rapid onset and mild-to-moderate side effects. | |
| Intrinsic excitation-inhibition imbalance in major depressive disorder. 2026 | observational cohort with transcriptomic and neurochemical decoding, plus a clinical trial component | 254 | Supports | Patients with MDD showed reduced cortical excitation-inhibition balance, and ketamine increased this balance in treatment-resistant depression. |
| Evaluating the Impact of Transcendental Meditation on Trauma Symptoms, Depression, Anxiety, and Sleep Problems Among Israeli Civilians Post-October 7, 2023: A Pilot Study. 2026 | pilot study | 39 | Supports | Participation in transcendental meditation was associated with statistically significant decreases in PTSD symptoms, depression, anxiety, and sleep problems among trauma-exposed civilians. |
| Vaporized mebufotenin leads to improvement in treatment‐resistant depression 2026 | RCT | Supports | An individualized one-day dosing regimen of vaporized 5-MeO-DMT was more effective than placebo in improving depressive symptoms in adults with treatment-resistant depression. | |
| Rapid clinical improvement after intravenous ketamine in an adolescent with treatment-resistant depression, severe obesity, and pseudo-Cushing syndrome: A case report. 2026 | case report | 1 | Supports | A single intravenous ketamine infusion led to rapid and sustained improvement in depressive symptoms in an adolescent with treatment-resistant depression and multiple medical comorbidities. |
| Intranasal esketamine use in treatment-resistant depression: mechanism of action, clinical adverse effects, contraindications, safe administration protocol and treatment process 2026 | review | Supports | Esketamine provides a novel therapeutic approach for depression by targeting NMDA receptors and intracellular signaling pathways, with a need for careful administration due to adverse effects and contraindications. | |
| Unraveling the mediating role of anxiety and depression: Cultivating mindfulness to improve quality of life in Parkinson's disease patients. 2026 | secondary analysis of baseline data from a clinical trial | 159 | Supports | Higher mindfulness levels were associated with reduced anxiety and depression and improved health-related quality of life, with anxiety and depression mediating these associations. |
| Divergent changes in perturbation-induced brain reconfiguration following depression treatment with psilocybin and escitalopram 2026 | observational cohort with pre- and post-treatment brain imaging | Mixed | Global brain network reconfiguration under perturbation increases after psilocybin and decreases after escitalopram treatment, suggesting distinct neural changes following each treatment. | |
| Dextromethorphan-bupropion-associated pharmacovigilance signals based on the FAERS database: An observational study. 2026 | observational pharmacovigilance study using FDA adverse event reporting system data | 3580 | Opposes | Dextromethorphan-bupropion is associated with adverse event signals, including psychiatric and nervous system disorders, with 65.3% of signals not listed in the drug's label. |
| Digital and In-Person Mindfulness-Based Interventions for University Students' Mental Health: A Systematic Review of Randomized Controlled Trials. 2026 | systematic review | 24 | Supports | Mindfulness-based interventions consistently reduce depression and generally improve anxiety among university students, with digital delivery showing comparable effectiveness to in-person formats. |
| Novel approaches in depression treatment: from rapid-acting antidepressants to personalized interventions. 2026 | review | Supports | Psilocybin has advanced to late-stage trials, and the SAINT protocol is FDA-cleared for treatment-resistant depression, while ongoing research explores EEG biomarker-guided and genetically guided personalized treatments. | |
| Pharmacokinetics and pharmacodynamics of orally administered S-ketamine in healthy participants. 2026 | randomized, double-blind, placebo-controlled, double-dummy, four-way cross-over study | 16 | Opposes | Oral S-ketamine has poor bioavailability and produces limited central nervous system effects compared to intravenous administration, with the lower oral dose lacking any effects. |
| Sex- and Age-Stratified Differences in Antidepressant Response to Intranasal Esketamine in Treatment-Resistant Depression: A Secondary Analysis of the REAL-ESK Study 2026 | secondary analysis of a prospective cohort study | 210 | Mixed | Intranasal esketamine was associated with substantial antidepressant improvement, and men showed a modest overall advantage in depression outcomes compared to women, though age-stratified sex differences were not statistically significant after correction. |
| THE IMPACT OF INTRANASAL ESKETAMINE ON TREATMENT-RESISTANT DEPRESSION: A SYSTEMATIC REVIEW 2026 | systematic review | Supports | Intranasal esketamine is associated with greater symptom improvement and higher response rates than control in TRD, but with more frequent adverse events such as dizziness and nausea. | |
| COMPARING ROUTES OF KETAMINE ADMINISTRATION IN TREATMENT-RESISTANT DEPRESSION: EFFICACY, SAFETY, AND OPTIMIZATION OF DOSING STRATEGIES 2026 | narrative review | Supports | Intravenous and intranasal routes are the best-supported options for rapid antidepressant response in treatment-resistant depression, while oral and sublingual forms may be useful for maintenance in resource-limited settings. | |
| PSILOCYBIN IN THE TREATMENT OF DEPRESSIVE DISORDERS: CLINICAL EVIDENCE AND ITS POTENTIAL TO ADDRESS THE GLOBAL MENTAL HEALTH CRISIS - A REVIEW 2026 | review | Supports | Psilocybin-assisted therapy offers rapid and lasting antidepressant effects for major depressive disorder and treatment-resistant depression, with symptom reduction often within the first week and benefits persisting 6–12 months. | |
| Blocking 5-HT2B receptors abolishes psilocybin’s efficacy in the rat forced swim test 2026 | experimental study | Supports | 5-HT2B receptors are required for psilocybin's rapid and sustained antidepressant-like behavioral effects in the forced swim test but not for its head-twitch response. | |
| Changes in hierarchical brain dynamics of rumination following mindfulness-based cognitive therapy for depression 2026 | RCT | 80 | Supports | MBCT plus treatment as usual increased brain hierarchy during rumination, and this increase was related to clinical and behavioral improvements. |
Mindfulness training significantly reduced anxiety and depression symptoms compared to control, with psychological resilience partially mediating these improvements.
RCT Sample size: 133
Ketamine offers rapid antidepressant effects in treatment-resistant depression and efficacy in pain, but long-term safety and protocol standardization remain unresolved.
review
Chronic psilocin microdosing did not affect depressive-like behavior, sociability, or neurogenesis, though a small anxiogenic effect was observed.
preclinical experimental study
Psychotherapy combined with ketamine may moderately prolong antidepressant effects, but data are heterogeneous and one study showed no advantage over ketamine monotherapy.
review
A 21-day mindfulness-based life coaching program was associated with significant reductions in stress, anxiety, and depression among medical students with mild-to-moderate distress.
cross-sectional screening followed by single-arm pre-post intervention Sample size: 100
Psychedelics, particularly psilocybin, ketamine, esketamine, and ayahuasca, show promise for treatment-resistant depression through mechanisms including neuroplasticity and corticolimbic enhancement.
review
This study aims to discover biomarkers associated with treatment resistance risk and molecular correlates of clinical response to esketamine nasal spray versus treatment as usual.
non-interventional, investigator-initiated, in-vitro study Sample size: 420
Esketamine reduces depressive symptoms more effectively than placebo or quetiapine, with rapid onset and mild-to-moderate side effects.
review
Patients with MDD showed reduced cortical excitation-inhibition balance, and ketamine increased this balance in treatment-resistant depression.
observational cohort with transcriptomic and neurochemical decoding, plus a clinical trial component Sample size: 254
Participation in transcendental meditation was associated with statistically significant decreases in PTSD symptoms, depression, anxiety, and sleep problems among trauma-exposed civilians.
pilot study Sample size: 39
An individualized one-day dosing regimen of vaporized 5-MeO-DMT was more effective than placebo in improving depressive symptoms in adults with treatment-resistant depression.
RCT
A single intravenous ketamine infusion led to rapid and sustained improvement in depressive symptoms in an adolescent with treatment-resistant depression and multiple medical comorbidities.
case report Sample size: 1
Esketamine provides a novel therapeutic approach for depression by targeting NMDA receptors and intracellular signaling pathways, with a need for careful administration due to adverse effects and contraindications.
review
Higher mindfulness levels were associated with reduced anxiety and depression and improved health-related quality of life, with anxiety and depression mediating these associations.
secondary analysis of baseline data from a clinical trial Sample size: 159
Global brain network reconfiguration under perturbation increases after psilocybin and decreases after escitalopram treatment, suggesting distinct neural changes following each treatment.
observational cohort with pre- and post-treatment brain imaging
Dextromethorphan-bupropion is associated with adverse event signals, including psychiatric and nervous system disorders, with 65.3% of signals not listed in the drug's label.
observational pharmacovigilance study using FDA adverse event reporting system data Sample size: 3580
Mindfulness-based interventions consistently reduce depression and generally improve anxiety among university students, with digital delivery showing comparable effectiveness to in-person formats.
systematic review Sample size: 24
Psilocybin has advanced to late-stage trials, and the SAINT protocol is FDA-cleared for treatment-resistant depression, while ongoing research explores EEG biomarker-guided and genetically guided personalized treatments.
review
Oral S-ketamine has poor bioavailability and produces limited central nervous system effects compared to intravenous administration, with the lower oral dose lacking any effects.
randomized, double-blind, placebo-controlled, double-dummy, four-way cross-over study Sample size: 16
Intranasal esketamine was associated with substantial antidepressant improvement, and men showed a modest overall advantage in depression outcomes compared to women, though age-stratified sex differences were not statistically significant after correction.
secondary analysis of a prospective cohort study Sample size: 210
Intranasal esketamine is associated with greater symptom improvement and higher response rates than control in TRD, but with more frequent adverse events such as dizziness and nausea.
systematic review
Intravenous and intranasal routes are the best-supported options for rapid antidepressant response in treatment-resistant depression, while oral and sublingual forms may be useful for maintenance in resource-limited settings.
narrative review
Psilocybin-assisted therapy offers rapid and lasting antidepressant effects for major depressive disorder and treatment-resistant depression, with symptom reduction often within the first week and benefits persisting 6–12 months.
review
5-HT2B receptors are required for psilocybin's rapid and sustained antidepressant-like behavioral effects in the forced swim test but not for its head-twitch response.
experimental study
MBCT plus treatment as usual increased brain hierarchy during rumination, and this increase was related to clinical and behavioral improvements.
RCT Sample size: 80
Points of agreement
- Mindfulness-based interventions consistently reduce depressive symptoms across diverse populations, including patients with anxiety/depression, medical students, university students, and Parkinson's disease patients.
- Ketamine and esketamine are effective rapid-acting antidepressants for treatment-resistant depression, with multiple reviews and trials supporting their efficacy.
- Psilocybin-assisted therapy shows rapid and sustained antidepressant effects in major depressive disorder and treatment-resistant depression.
- Psychedelics and ketamine may work through neuroplasticity and modulation of brain network dynamics.
Conflicts
- One study found that chronic psilocin microdosing had no effect on depressive-like behavior in rats, contrasting with the positive findings for full-dose psychedelics.
- Oral S-ketamine showed poor bioavailability and limited CNS effects, conflicting with the efficacy of intravenous and intranasal routes.
- A pharmacovigilance study identified adverse event signals for dextromethorphan-bupropion, including psychiatric disorders, which may temper its perceived benefit.
- Sex differences in esketamine response were found in one study but not consistently across age groups.
Gaps
- Long-term durability of antidepressant effects beyond 12 months is not well established for esketamine and other rapid-acting treatments.
- Most psychedelic trials have small sample sizes and lack adequate blinding, limiting the strength of conclusions.
- Optimal dosing and protocol standardization for ketamine and esketamine across routes remain unresolved.
- The role of specific receptor subtypes (e.g., 5-HT2B) in psilocybin's antidepressant effects needs further clinical validation.
- Biomarker-guided personalized treatments are still in early stages, with limited evidence for clinical implementation.